YA-102
Parkinson's Disease
PreclinicalActive
Key Facts
About Yoda Therapeutics
AI‑powered biotech developing disease‑modifying CNS therapies, with a Phase‑II orphan drug candidate for Multiple System Atrophy.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |
| Bezisterim (NE3107) | BioVie | Phase 2 |